Methods and materials for treating inflammatory diseases
First Claim
Patent Images
1. A method for treating an inflammatory disease, said method comprising:
- a) identifying a host in need of an anti-inflammatory treatment, wherein said host has inflamed tissue, and b) administering a pharmaceutically effective amount of an IL-16 polypeptide or an IL-16-mimicking molecule to said host under conditions such that the expression of an inflammatory cytokine in the region of said inflamed tissue is reduced.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods and materials related to the treatment of inflammatory diseases such as rheumatoid arthritis. Specifically, the invention provides methods and materials for treating inflammation by reducing production of an inflammatory cytokine such as IFN-γ, IL-1β, and TNF-α. The invention also provides methods and materials for identifying reagents that can be used to treat inflammatory diseases. Specifically, the invention provides non-human animals containing human synovial tissue as well as methods for using such non-human animals to determine the influence of various test reagents on the inflamed state of human synovial tissue.
8 Citations
54 Claims
-
1. A method for treating an inflammatory disease, said method comprising:
-
a) identifying a host in need of an anti-inflammatory treatment, wherein said host has inflamed tissue, and b) administering a pharmaceutically effective amount of an IL-16 polypeptide or an IL-16-mimicking molecule to said host under conditions such that the expression of an inflammatory cytokine in the region of said inflamed tissue is reduced. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
- 9. A method of treating an inflammatory disease in a host, said method comprising providing nucleic acid to said host, wherein said nucleic acid encodes an IL-16 polypeptide and wherein said host expresses said IL-16 polypeptide from said nucleic acid such that the expression of an inflammatory cytokine is reduced in said host.
- 17. A method of treating an inflammatory disease in a host, said method comprising administering, to said host, cells that reduce the expression of an inflammatory cytokine.
- 27. A pharmaceutical composition for treating an inflammatory disease in a host, said composition comprising an IL-16 polypeptide or an IL-16-mimicking molecule and an immunosuppressive cytokine, wherein the administration of said composition to said host reduces the expression of an inflammatory cytokine in said host.
- 35. A non-human animal comprising human synovial tissue.
-
47. A method for identifying a treatment reagent that reduces inflammation, said method comprising:
-
a) administering a test reagent to a non-human animal having human synovial tissue, wherein at least a portion of said human synovial tissue is inflamed, and b) determining if said administration of said test reagent reduces said inflammation, wherein a reduction in inflammation indicates that said test reagent is a treatment reagent. - View Dependent Claims (48)
-
-
49. An article of manufacture comprising packaging material and an IL-16 polypeptide or IL-16-mimicking molecule, wherein said packaging material comprises a label or package insert indicating that said IL-16 polypeptide or IL-16-mimicking molecule can be administered to a host for the purpose of treating an inflammatory disease.
-
50. An article of manufacture comprising packaging material and nucleic acid encoding an IL-16 polypeptide, wherein said packaging material comprises a label or package insert indicating that said nucleic acid can be administered to a host for the purpose of treating an inflammatory disease.
-
51. An article of manufacture comprising packaging material and cells that reduce the expression of an inflammatory cytokine, wherein said packaging material comprises a label or package insert indicating that said cells can be administered to a host for the purpose of treating an inflammatory disease.
-
52. The use of an IL-16 polypeptide or an IL-16-mimicking molecule in the manufacture of a medicament for treating an inflammatory disease in a host in need of an anti-inflammatory treatment, wherein said host has inflamed tissue, and wherein administering a pharmaceutically effective amount of said medicament to said host reduces the expression of an inflammatory cytokine in the region of said inflamed tissue.
-
53. The use of a nucleic acid in the manufacture of a medicament for treating an inflammatory disease in a host in need of an anti-inflammatory treatment, wherein said nucleic acid encodes an IL-16 polypeptide, wherein said host has inflamed tissue, and wherein administering said medicament to said host reduces the expression of an inflammatory cytokine in the region of said inflamed tissue.
-
54. The use of cells in the manufacture of a medicament for treating an inflammatory disease in a host in need of an anti-inflammatory treatment, wherein said host has inflamed tissue, and wherein administering said medicament to said host reduces the expression of an inflammatory cytokine in the region of said inflamed tissue.
Specification